Opioid Use Disorder Market Analysis

OUD Drug Market Analysis

To get key market trends

  Download Free Sample

Based on drug type, the opioid use disorder market is segmented into buprenorphine, methadone, and naltrexone. In 2022, the buprenorphine market segment held the largest market share, and this trend is predicted to continue during the forecast period. The factors that account for the highest share of the market is increased use of buprenorphine as it is an effective option to treat opioid dependence, reduce cravings, and improve the quality of life for patients undergoing addiction treatment. Buprenorphine is currently available in two forms- alone and in combination with the opioid receptor antagonist naloxone. Both formulations of buprenorphine are effective for the treatment of opioid use disorders.
 

By age group, the opioid use disorder market is segmented into 19 to 40, 41 to 60, and 61 & over. The 19 to 40 age group segment dominated the market in 2022 and is expected to continue this trend throughout the forecast period, owing to the changes in lifestyle habits as well as increased use of opioid as pain treatment in young and middle age population.
 

For instance, in 2020, national institute on drug abuse (NIDA) estimated around 2.7 million people aged 12 or older, in the US had an opioid use disorder (OUD) in the past 12 months—including 2.3 million people with a prescription opioid use disorder.
 

Based on route of administration, the opioid use disorder market is segmented into intravenous and oral. The oral segment projected to account for highest market share during the forecast period due to the availability of various types of OUD drugs in different dosages in the oral form.
 

By distribution channel, the opioid use disorder market hospital pharmacies, online pharmacies, and retail pharmacies. Hospital pharmacies segment anticipated to account for highest share in 2022.
 

Hospitals are primary care facilities with abundant presence of well trained, skilled staff and professionals who assist patients in received effective treatments.

North America dominated the OUD market and accounted for a revenue share of over 49.3% in 2022 owing to increase the number of product launches for treatment of opioids use disorder, increasing prescriptions of opioids, increasing opioid consumers, increasing deaths from overdose of opioids, and well-established opioid industry in North America.